Indisetron (INN; trade name Sinseron) is a drug used for prophylaxis of chemotherapy-induced nausea and vomiting. It was approved by Japan's Pharmaceuticals and Medical Devices Agency in 2004.

Indisetron
Clinical data
Trade namesSinseron
Other namesN-3389
ATC code
  • none
Legal status
Legal status
  • Rx in Japan
Identifiers
  • N-[(1R,5S)-3,9-Dimethyl-3,9-diazabicyclo[3.3.1]nonan-7-yl]-1H-indazole-3-carboxamide
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
Chemical and physical data
FormulaC17H23N5O
Molar mass313.405 g·mol−1
3D model (JSmol)
  • CN1C[C@H]2CC(C[C@@H](C1)N2C)NC(=O)C3=NNC4=CC=CC=C43
  • InChI=1S/C17H23N5O/c1-21-9-12-7-11(8-13(10-21)22(12)2)18-17(23)16-14-5-3-4-6-15(14)19-20-16/h3-6,11-13H,7-10H2,1-2H3,(H,18,23)(H,19,20)/t11?,12-,13+
  • Key:MHNNVDILNTUWNS-YHWZYXNKSA-N

Indisetron exerts its effects as a dual serotonin 5-HT3 and 5-HT4 receptor antagonist.[1][2]

See also

edit

References

edit
  1. ^ "Indisetron". Inxight: Drugs. National Center for Advancing Translational Sciences, National Institutes of Health.
  2. ^ Tsukagoshi S (April 2005). "[Introduction of novel anti-emetic agent, indisetron hydrochloride, developed recently in Japan]". Gan to Kagaku Ryoho. Cancer & Chemotherapy (in Japanese). 32 (4): 567–73. PMID 15853230.